The London Life Sciences team advised Gadeta B.V. on its strategic collaboration with Kite, a Gilead company (Nasdaq: GILD), to develop novel gamma delta T cell receptors therapies in various cancers. Under the financial terms, Kite will provide research and development funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones. Additionally, Kite will make an upfront purchase of equity in Gadeta from Gadeta’s shareholders and may acquire additional equity in Gadeta upon achievement of certain R&D milestones. Kite will have the exclusive option to acquire Gadeta.
Founded in 2015, Gadeta has developed a technology platform based on combinatorial T cell receptor exchange (CTE) to create optimized gamma delta T cell receptors (TCRs) with an enhanced anti-cancer reactivity. The platform is based on research from Prof. Jürgen Kuball from University Medical Center Utrecht and Chief Scientific Officer at Gadeta. Gadeta’s investigational cell-based anti-cancer products called T Cells Engineered To Express A Defined Gamma Delta TCR have therapeutic potential for combating and eradicating both hematological and solid tumors. Funds managed by Medicxi, a Goodwin client, are the largest shareholder in Gadeta.
The Goodwin team was led by partners Graham Defries, Andrew Harrow and associates Emily Beman and Kenny MacLeod.
For additional details on the collaboration, please read the press release.